EU307 CAR-T Cell
Phase 1Cell therapy
EU307 CAR-T Cell is one of 50 biologic programs targeting Efficacy. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
139 competitors in Efficacy
#DrugCompanyPhaseTrials
1Rayos
RRoxane Laboratories
Phase 3
Paraplatin
AAvyxa
Phase 3
Lesinurad
EEsperion Therapeutics, Inc.
Phase 3
Insulin 320
Novo NordiskPhase 3
Endothelin Receptor Antagonist
RRadboud University Medical Center
Phase 3
Cetaphil
GGalderma R&D
Phase 3
Veracept
SSebela Women's Health Inc.
Phase 3
Aralen
SanofiPreclinical
Primaquine
SanofiPreclinical
Proamatine
TakedaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for EU307 CAR-T Cell. EMBL-EBI & Wellcome Sanger Institute.
- [4]